Incyte Corporation (LON:0J9P)
99.50
+0.83 (0.85%)
Dec 30, 2025, 12:16 PM BST
Incyte Revenue
Incyte had revenue of $1.37B USD in the quarter ending September 30, 2025, with 20.05% growth. This brings the company's revenue in the last twelve months to $4.81B, up 18.09% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.81B
Revenue Growth
+18.09%
P/S Ratio
4.04
Revenue / Employee
$1.84M
Employees
2,617
Market Cap
14.45B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
| Dec 31, 2018 | 1.88B | 345.67M | 22.50% |
| Dec 31, 2017 | 1.54B | 430.50M | 38.93% |
| Dec 31, 2016 | 1.11B | 351.97M | 46.70% |
| Dec 31, 2015 | 753.75M | 242.26M | 47.36% |
| Dec 31, 2014 | 511.50M | 508.45M | 16,696.72% |
| Dec 31, 2013 | 3.05M | -294.01M | -98.97% |
| Dec 31, 2012 | 297.06M | 202.60M | 214.50% |
| Dec 31, 2011 | 94.46M | -75.42M | -44.40% |
| Dec 31, 2010 | 169.88M | 160.61M | 1,733.55% |
| Dec 31, 2009 | 9.27M | 5.35M | 136.41% |
| Dec 31, 2008 | 3.92M | -30.52M | -88.62% |
| Dec 31, 2007 | 34.44M | 6.80M | 24.59% |
| Dec 31, 2006 | 27.64M | 19.80M | 252.32% |
| Dec 31, 2005 | 7.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Incyte News
- 7 days ago - Incyte Secures Dual Approvals In Japan For Zynyz And Minjuvi - Nasdaq
- 7 days ago - Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Nasdaq
- 8 days ago - Japan Approves Incyte's (INCY) Zynyz for First-Line SCAC Treatment - GuruFocus
- 8 days ago - Incyte (INCY) Secures Japanese Approval for Minjuvi Combination Therapy - GuruFocus
- 8 days ago - Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
- 8 days ago - Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer - Business Wire
- 11 days ago - EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Nasdaq
- 11 days ago - Best Defensive Stocks To Balance Tech Sector Volatility - Seeking Alpha